GlassScriptPhysician profile
Michael D Canty
NPI 1003912783
$3,752.94
in general payments reported to CMS, 2019-2025
27 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $227 · 2021: $569 · 2022: $578 · 2023: $768 · 2024: $1,037 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Education: $99.00 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.35 |
| Education | $99.00 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,203.82 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $345.41 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $227.33 | 2021-2025 | Viberzi, Linzess, Creon |
| Boston Scientific Corporation | $210.06 | 2019-2025 | Exalt Model D, Spyglass |
| Lilly USA, LLC | $202.80 | 2024-2025 | Omvoh, Zepbound |
| Evoke Pharma, INC. | $164.32 | 2021-2025 | Gimoti |
| Olympus America INC. | $135.09 | 2021-2024 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Takeda Pharmaceuticals U.S.A., INC. | $129.92 | 2019-2025 | Eohilia, Entyvio |
| Qol Medical, LLC | $123.64 | 2023-2024 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $120.29 | 2020-2023 | |
| Ardelyx, INC. | $113.09 | 2023-2024 | Ibsrela |
| Daiichi Sankyo INC. | $111.47 | 2021-2022 | |
| Madrigal Pharmaceuticals | $97.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $89.39 | 2022-2023 | Talicia |
| Celgene Corporation | $89.34 | 2021-2023 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $60.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.26 | 2023-2024 | Dificid |
| Celltrion USA INC. | $39.27 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $35.27 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $35.11 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $34.94 | 2023 | Sutab |
| Regeneron Healthcare Solutions, INC. | $31.82 | 2023 | Dupixent |
| Shionogi INC | $26.90 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.15 | 2024 | Voquezna |
| Genzyme Corporation | $17.02 | 2024 | |
| Pfizer INC. | $15.58 | 2021 | |
| Amgen INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Canty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.